 |
特任助教 櫻井 遊 （Yu Sakurai） 生年月日：１９８５年（昭和６０年）１２月１９日 E-mail：yu-m☆pharm.hokudai.ac.jp （☆は＠です） |
学歴
２０１３年３月−２０１０年４月
北海道大学大学院生命科学院生命科学専攻生命医薬科学コース 博士後期課程
２０１０年３月−２００８年４月
北海道大学大学院生命科学院生命科学専攻生命医薬科学コース 修士課程
２００８年３月―２００４年４月
北海道大学薬学部総合薬学科
研究歴
現在−２０１３年４月
北海道大学大学院薬学研究院 未来創剤学研究室 特任助教
賞罰
2017年1月北海道大学研究総長賞（奨励賞）を受賞
2012年6月
北大クラーク記念財団より「博士後期課程在学生海外派遣助成（学会等発表）」の助成金
2011年7月
Oligonucleotide Therapeutic Society 7th annual meeting，Copenhagen (Denmark) にてTravel Grant
2009年10月
Asian Federation for Pharmaceutical Sciences，Fukuoka (Japan) にてThe AFPS Nagai-Shunkri Pre-doctoral Oral Presentation Awardを受賞
2009年10月
同学会にてThe AFPS Nagai-Shunkri Pre-doctoral Best Paper Awardを受賞
所属学会
日本薬学会、日本薬剤学会、日本DDS学会信条
解決に必要なのは、努力よりひらめきだ好きなもの
旅行、車を運転すること、お酒特任助教：櫻井 遊 (Sakurai Yu)
原著論文
| 1. | Yamamoto S, Sakurai Y, Harashima H. Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption. Int J Pharm 536: 42-49 (2018) [PubMed ID: 29126905] |
| 2. | Sakurai Y, Mizumura W, Murata M, Hada T, Yamamoto S, Ito K, Iwasaki K, Katoh T, Goto Y, Takagi A, Kohara M, Suga H, Harashima H. Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting. Mol Pharm 14: 3290-3298 (2017) [PubMed ID: 28789523] |
| 3. | Sakurai Y, Mizumura W, Murata M, Hada T, Yamamoto S, Ito K, Iwasaki K, Katoh T, Goto Y, Takagi A, Kohara M, Suga H, Harashima H. Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting. Mol Pharm 14(10): 3290-3298 (2017). [Pubmed ID: 28789523] |
| 4. | Yamada Y, Munechika R, Kawamura E, Sakurai Y, Sato Y, Harashima H. Mitochondrial Delivery of Doxorubicin Using MITO-Porter Kills Drug-Resistant Renal Cancer Cells via Mitochondrial Toxicity. J Pharm Sci 106(9):2428-2437 (2017). [Pubmed ID: 28478130] |
| 5. | Toriyabe N, Sakurai Y, Kato A, Yamamoto S, Tange K, Nakai Y, Akita H, Harashima H. The Delivery of Small Interfering RNA to Hepatic Stellate Cells Using a Lipid Nanoparticle Composed of a Vitamin A-Scaffold Lipid-Like Material. J Pharm Sci 106(8): 2046-2052 (2017). [PubMed ID: 28456722] |
| 6. | Yamamoto S†, Kato A†, Sakurai Y†, Hada T, Harashima H. Modality of tumor endothelial VEGFR2 silencing-mediated improvement in intratumoral distribution of lipid nanoparticles. J Control Release, 251: 1-10 (2017). [Pubmed ID: 28192155] †: equally contributed to the manuscript |
| 7. | Sakurai Y, Hada T, Harashima H. Scalable preparation of poly(ethylene glycol)-grafted siRNA-loaded lipid nanoparticles using a commercially available fluidic device and tangential flow filtration. J Biomater Sci Polym Ed, 1-11 (2017). [Pubmed ID : 28157422] |
| 8. | Nakamura T, Noma Y, Sakurai Y, Harashima H. Modifying Cationic Liposomes with Cholesteryl-PEG Prevents Their Aggregation in Human Urine and Enhances Cellular Uptake by Bladder Cancer Cells. Biol Pharm Bull, 40(2):234-237 (2017). [Pubmed ID: 28154264] |
| 9. | Sakurai Y, Hada T, Yamamoto S, Kato A, Mizumura W, Harashima H. "Remodeling of the extracellular matrix by endothelial cell-targeting siRNA improves the EPR-based delivery of 100 nm particles.", Mol Ther, in press [PubMed ID: 27633444] |
| 10. | Kazuaki K, Suemitsu E, Sato Y, Sakruai Y, Harashima H. "Liver-specific silencing of lipin1 reduces fat mass as well as hepatic triglyceride biosynthesis in mice", Biol Pharm Bull, 39(10): 1653-1661 (2016). [Pubmed ID: 27725442] |
| 11. | Watanabe A, Tanaka H, Sakurai Y, Tange K, Nakai Y, Ohkawara T, Takeda H, Harashima H, Akita H. "Effect of particle size on their accumulation in an inflammatory lesion in a dextran sulfate sodium (DSS)-induced colitis model.", Int J Pharm, 509(1-2):118-122 (2016). [PubMed ID: 27231121] |
| 12. | Sano N, Tamura T, Toriyabe N, Nowatari T, Nakayama K, Tanoi T, Murata S, Sakurai Y, Hyodo M, Fukunaga K, Harashima H, Ohkohchi N. "New drug delivery system for liver sinusoidal endothelial cells for ischemia-reperfusion injury.", World J Gastroenterol, 21(45): 12778-12786 (2015). [Pubmed ID: 26668502] |
| 13. | Tanoi T, Tamura T, Sano N, Nakayama K, Fukunaga K, Zheng YW, Akhter A, Sakurai Y, Hayashi Y, Harashima H, Ohkohchi N. Protecting liver sinusoidal endothelial cells suppresses apoptosis in acute liver damage, Hepatol Res, 21(45): 118-122 (2016). [PubMed ID: 26668502] |
| 14. | Hada T, Sakurai Y, Harashima H. "Optimization of a siRNA Carrier Modified with a pH-Sensitive Cationic Lipid and a Cyclic RGD Peptide for Efficiently Targeting Tumor Endothelial Cells." Pharmaceutics. (2015) 7(3):320-333. |
| 15. | Sakurai Y, Takashi M, Hada T, Harashima H. "The Efficient Packaging of Plasmid DNA using a pH Sensitive Cationic Lipid for Delivery to Hepatocytes." Biol Bull Pharm. (2015) 38(8):1185-1191. |
| 16. | Sato S, Li K, Kameyama T, Hayashi T, Ishida Y, Murakami S, Watanabe T, Iijima S, Sakurai Y, Tsutsumi S, Sato Y, Akita H, Rice NC, Harashima H, Kohara M, Takana Y, Takaoka A, "RIG-I dually functions as an innate sensor and as a direct antiviral factor for hepatitis B virus." Immunity. (2015) 42(1):123-132. |
| 17. | Afsana A, Hayashi Y, Sakurai Y, Ohga N, Hida K, Harashima H. "Ligand density at the surface of a nanoparticle and different uptake mechanism: two important factors for successful siRNA delivery to liver endothelial cells." Int J Pharm. (2014) 475(1-2): 227-237. |
| 18. | Ara N, Matsuda T, Hyodo M, Sakurai Y, Ohga N, Hida K, Harashima H. "The construction of an aptamer modified liposomal system targeted to tumor endothelial cells." Biol Bull Pharm. (2014) 37(11):1742-1749. |
| 19. | Sakurai Y, Hatakeyama H, Akita H, Harashima H. "Improvement of doxorubicin effect using liposomal anti-polo like kinase 1 siRNA in human renal cell carcinomas." Mol Pharm. (2014) 11(8): 2713-2719. |
| 20. | Ara N, Matsuda T, Hyodo M, Sakurai Y, Hatakeyama H, Ohga N, Hida K, Harashima H. "An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells." Biomaterials. (2014) 35(25): 7110-7120. |
| 21. | Hayashi Y, Suemitsu E, Kajimoto K, Sato Y, Akhter A, Sakurai Y, Hatakeyama H, Hyodo M, Kaji N, Baba Y, Harashima H. "Hepatic monoacylglycerol o-acyltransferase 1 as a promising therapeutic target for steatosis, obesity and type2 diabetes." Mol Ther Nucleic Acids. (2014) 3:e154. |
| 22. | Sakurai Y, Hatakeyama H, Sato Y, Hyodo M, Akita H, Ohga N, Hida K, Harashima H. "RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system." J Control Release. (2014) 173: 110-118. |
| 23. | Akhter A, Hayashi Y, Sakurai Y, Ohga N, Hida K, Harashima H. "A liposomal delivery system that targets liver endothelial cells based on a new peptide motif present in the ApoB-100 sequence." Int J Pharm. (2013) 456(1):195-201. |
| 24. | Sakurai Y, Hatakeyama H, Sato Y, Hyodo M, Akita H, Harashima H. "Gene Silencing via RNAi and siRNA quantification in Tumor Tissue using MEND, a Liposomal siRNA Delivery System." Mol Ther. (2013) 21(6):1195-1203. |
| 25. | Sato Y, Hatakeyama H, Sakurai Y, Hyodo M, Akita H, Harashima H. "A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo." J Control Release. (2012) 163(3): 267-276. |
| 26. | Sakurai Y, Hatakeyama H, Sato Y, Akita H, Takayama K, Kobayashi S, Futaki S, Harashima H. "Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA." Biomaterials. (2011) 32(24): 5733-5742. |
| 27. | Sakurai Y, Hatakeyama H, Akita H, Oishi M, Nagasaki Y, Futaki S, Harashima H. "Efficent siRNA delivery to tumor cells using the combination of octaarginine, GALA and tumor-specific, cleavable PEG system." Biol Pharm Bull. (2009) 32(5): 928-932. |
Page Up総説
英文総説| 1. | Nichols JW, Sakurai Y, Harashima H, Bae YH. Nano-sized drug carriers: Extravasation, intratumoral distribution, and their modeling. J Control Release in press. |
| 2. | Sato Y, Sakurai Y, Kajimoto K, Nakamura T, Yamada Y, Akita H, Harashima H. Innovative technologies in Nanomedicines: from passive targeting to active targeting/from controlled pharmacokinetics to controlled intracellular pharmacokinetics. Macromol Biosci, in press. |
| 3. | Hida K, Maishi N, Sakurai Y, Hida Y, Harashima H. "Heterogeneity of tumor endothelial cells and drug delivery." Adv Drug Deliv Rev, 9(Pt B): 140-147 (2016). |
| 4. | Sakurai Y, Hada T, Harashima H. "Preparation of a Cyclic RGD: Modified Liposomal SiRNA Formulation for Use in Active Targeting to Tumor and Tumor Endothelial Cells." Methods Mol Biol. (2016) 1364:63-69. |
| 5. | Sakurai Y, Kajimoto K, Harashima H. "Anti-angiogenic nanotherapy via active targeting systems to tumors and adipose tissue vasculature." Biomater Sci. (2015) 3(9):1253-1265. |
| 6. | Sakurai Y, Kajimoto K, Hatakeyama H, Harashima H. Acvances in an active and passive targeting to tumor and adipose tissues. Expert Opin Drug Deliv. (2014) 7:1-12. |
| 7. | Hyodo M, Sakurai Y, Akita H, Harashima H. Programmed Packaging for gene delivery. J Control Release. (2014) 193:316-23. |
和文総説
| 1. | 櫻井 遊，梶本 和昭，原島 秀吉．「血管を標的とする薬物送達システムに基づいた新しい治療法」，Dementia Japana (2016) 30(1): 30-40. |
| 2. | 櫻井遊．「核酸医薬の現状と創薬のパラダイムシフト」，道薬誌 一般財団法人北海道薬剤師会編集発行）(2013) 30(20): 4-10. |
| 3. | 櫻井遊，畠山浩人，秋田英万，原島秀吉．「多機能性エンベロープ型ナノ構造体によるsiRNAデリバリー」，生体の科学 (2012)63(2): 113-119. |
教育
学部担当授業科目：
先端生物科学実験法 II、薬剤学実習
その他
| 1. | T. Ishii, Sakurai Y. “Challenges and new directions for next-generation drug delivery system (DDS) research based on nano-technology”. YAKUGAKU ZASSHI 132(12): 1345-1346 (2012) |
特許
| 1. | 特願2012-119521，発明者：原島秀吉， 畠山浩人，佐藤悠介，兵藤守，櫻井遊，秋田英万，名称：脂質膜構造体にpH依存性カチオン性を付与する剤, それによりpH依存性カチオン性が付与された脂質膜構造体および脂質膜構造体の製造方法，出願人：株式会社バイオメッドコア，出願日：2012年5月25日 |
| 2. | 特願2010-39667，発明者：原島秀吉，秋田英万，榎戸薫，畠山浩人，櫻井遊，名称：機能性ポリペプチド及び当該ポリペプチドで修飾された脂質膜構造体，出願人：国立大学法人 北海道大学，出願日：2010年2月25日 |
招待講演
| 1. | 佐藤悠介，畠山浩人，櫻井遊，兵藤守，秋田英万，原島秀吉．「siRNA搭載pH応答性MENDの構築とin vivoへの応用」．日本薬学会第133年会，2012年3月30日，札幌 |
| 2. | 櫻井遊，畠山浩人，秋田英万，原島秀吉，「細胞内動態制御に基づくin vivo siRNAデリバリーシステムの構築」，薬剤学会第26年会．2011年５月31日，東京 |